Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma

Medical Oncology

Volumn 19, Issue 2, 2002, Pages 87-104

  Schwarzenbach, Heidi ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Alkylating agents; BMMCs; Bone marrow; Doxorubicin; Overexpression; RT PCR; Verapamil

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; VERAPAMIL; VINCRISTINE; ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; RIBONUCLEOPROTEIN; TUMOR PROTEIN;

ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG POTENTIATION; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INCIDENCE; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; PATHOGENESIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR CELL LINE; CELL CULTURE; GENETICS; ISOLATION AND PURIFICATION;

ANTINEOPLASTIC AGENTS; DNA, COMPLEMENTARY; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; HUMAN; MULTIPLE MYELOMA; NEOPLASM PROTEINS; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED; VAULT RIBONUCLEOPROTEIN PARTICLES; VERAPAMIL; HUMANS;

EID: 0036017506     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:19:2:87     Document Type: Article

References (51)

1. Chemotherapy resistance in acute myeloid leukaemia
2. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia
3. From MDR to MXR: New understanding of multidrug resistance systems, their properties and clinical significance
4. A new structural model for P-glycoprotein
5. Up-regulation of transporters of the MRP family by drugs and toxins
6. Modulation of multidrug resistance in a cancer cell line by anti-multidrug resistance-associated protein (MRP) ribozyme
7. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein
8. Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity
9. Glutathione-dependent binding of a photoaffinity analog of agosterol A to the C-terminal half of human multidrug resistance protein
10. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer
11. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia
12. Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia
13. Multidrug resistance-associated protein (MRP) in haematological malignancies
14. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma
15. Drug resistance-associated marker Lrp of prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma
16. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia
17. P-glycoprotein expression in human plasma cell myeloma: Correlation with prior chemotherapy
18. Analysis of multidrug-resistance (MDR-1) glycoprotein and CD56 expression to separate monoclonal gammopathy from multiple myeloma
19. Expressions of DNA topoisomerase I and II gene and the genes possibly related to drug resistance in human myeloma cells
20. Levels of expression of the mdr1 gene and glutathione S-transferase genes 2 and 3 and response to chemotherapy in multiple myeloma
21. Quantitative polymerase chain reaction analysis of mdr1 mRNA in multiple myeloma cell lines and clinical specimens
22. Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining
23. MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents
24. Multidrug-resistant myeloma: Laboratory and clinical effects of verapamil as a chemosensitizer
25. Modulation of multidrug-resistant multiple myeloma by cyclosporin
26. Clinical modulation of multidrug resistance in multiple myeloma: Effect of cyclosporine on resistant tumor cells
27. VAD-cyclosporine therapy for VAD-resistant multiple myeloma
28. Proposed guidelines for protocol studies. II. Plasma cell myeloma
29. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype
30. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein
31. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: Association with level of drug resistance and drug accumulation
32. RPMI 8226 human myeloma cells develop atypical multidrug resistance when mimicking clinical doxorubicin treatment in vitro
33. Overexpression of MDR/P-glycoprotein and MRP but not LRP is mutually exclusive in multidrug resistant human myeloma cells selected with doxorubicin
34. Drug transport variants without P-glycoprotein overexpression from a human squamous lung cell line after selection with doxorubicin
35. In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain
36. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells
37. Molecular structure of the human cytoplasmic beta-actin gene: Interspecies homology of sequences in the introns
38. Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug-resistance
39. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies
40. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance
41. Detection of the M(r) 190,000 multidrug resistance protein, MRP, with monoclonal antibodies
42. Chemotherapy induces or increases expression of multidrug resistance-associated protein in malignant melanoma cells
43. Expression of mdr-1 in refractory lymphoma: Quantitation by polymerase chain reaction and validation of the assay
44. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations
45. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma
46. Prognostic factors in multiple myeloma: Selection using Cox's proportional hazard model
47. Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction
48. Phenotypic difference of normal plasma cells from mature myeloma cells
49. Identification of immature and mature myeloma cells in the bone marrow of human myelomas
50. Anti-CD38-blocked ricin: An immunotoxin for the treatment of multiple myeloma